Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron VariantSammy Huygens, Bart Rijnders, Marion Koopmans et al.|Clinical Infectious Diseases|2022Cited by 50
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patientsSammy Huygens, Bart Rijnders, Britt Snoek et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 23
Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort StudySammy Huygens, Bas B. Oude Munnink, Corine H. GeurtsvanKessel et al.|Clinical Infectious Diseases|2024Cited by 15
High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantSammy Huygens, Bart Rijnders, Marion Koopmans et al.|medRxiv|2022Cited by 11